Accelerated Approval and Expensive Drugs—A Challenging Combination

The authors examine the tension between the FDA’s accelerated approval pathway and the increasingly high prices manufacturers set for these products, creating a situation where insurers and patients pay premium prices for drugs whose real-world effectiveness has not yet been confirmed.